D-0095-2017 Class III Terminated
FDA drug recall D-0095-2017 was initiated by Teva Pharmaceuticals USA on Sep 13, 2016 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: potential failure to meet the specification for Impurity D throughout shelf-life. The recall status is terminated (terminated May 5, 2017). Affected quantity: 11,214 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Oct 19, 2016
- Initiation Date
- Sep 13, 2016
- Termination Date
- May 5, 2017
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 11,214 vials
Product description
mitoXANTRONE Injection USP (concentrate), 20 mg/10 mL (2 mg/mL), 10 mL Multiple Dose Vial, Rx only, Teva Parenteral Medicines, Inc., Irvine, CA 92618, NDC 0703-4685-01.
Reason for recall
Failed Impurities/Degradation Specifications: potential failure to meet the specification for Impurity D throughout shelf-life.
Distribution pattern
Nationwide
Code information
Lot Numbers: 31318574B, Exp 09/16; 31319610B, Exp 07/17; 31320058B, Exp 11/17; 31320497B, Exp 12/17; 31320744B, Exp 02/18
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0095-2017
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026